886230-74-6

Basic information

• Product Name: 3-Iodo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
• Synonyms: 3-Iodo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole;3-iodo-6-nitro-1-(tetrahydropyran-2-yl) -1H-indazole
• CAS NO: 886230-74-6
• Molecular Formula: C₁₂H₁₂IN₃O₃
• Molecular Weight: 373.14645
• Product Categories: axitinib intermediate;Intermediate of Axitinib
• Mol File: 886230-74-6.mol

Chemical Properties

• Boiling Point: 504.111 °C at 760 mmHg
• Flash Point: 258.678 °C
• Appearance: /
• Density: 2.01
• Storage Temp.: 2-8°C
• PKA: -2.96±0.50(Predicted)
• CAS DataBase Reference: 3-Iodo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Iodo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(886230-74-6)
• EPA Substance Registry System: 3-Iodo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(886230-74-6)

Safety Data

• Hazardous Substances Data: 886230-74-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Iodo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole is used as a reactant in the preparation of carbazole derivatives, which are known as kinase inhibitors. Kinase inhibitors are a class of drugs that target specific enzymes involved in cellular signaling pathways, playing a crucial role in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. By inhibiting the activity of these kinases, carbazole derivatives can potentially be used to treat a range of diseases, including cancer and other proliferative disorders.
In the synthesis of carbazole derivatives, 3-Iodo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole serves as a key intermediate, providing a foundation for the construction of the desired carbazole scaffold. The presence of the iodine and nitro groups in the molecule allows for further functionalization and modification, enabling the development of carbazole derivatives with tailored properties and improved biological activity.
Overall, 3-Iodo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole is a valuable compound in the field of medicinal chemistry, with its potential use in the development of novel kinase inhibitors highlighting its significance in the search for new therapeutic agents.

Upstream product

• 99-55-8 2-methyl-5-nitroaniline 
• 110-87-2 3,4-dihydro-2H-pyran 
• 150187-67-0 6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole 
• 7597-18-4 6-nitroindazole 
• 70315-70-7 3-iodo-6-nitro-1H-indazole 

Downstream Products

• 886230-76-8 (Ε)-6-amino-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)indazole 
• 1012060-43-3 methyl 6-(2-(1-(tetrahydro-2H-pyran-2-yl)-3-((E)-2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamido)hexanoate 
• 1012060-44-4 methyl 6-(2-(3-((E)-2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamido)hexanoate 
• 1012056-56-2 N-(5-(hydroxycarbamoyl)pentyl)-2-(3-((E)-2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamide 
• 1133966-04-7 (E)-methyl 5-(2-(3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-ylthio)phenoxy)pentanoate 
• 1133966-05-8 (E)-methyl 5-(2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)phenoxy)pentanoate 
• 1133966-14-9 (E)-2-(3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-ylthio)benzenamine 
• 1133966-15-0 (E)-methyl 5-(2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)phenylamino)pentanoate 
• 1133966-18-3 (E)-ethyl 6-oxo-6-(2-(3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-ylthio)phenylamino)hexanoate 
• 1133966-19-4 (E)-ethyl 6-oxo-6-(2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)phenylamino)hexanoate 
• 1133966-20-7 (E)-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzenamine 
• 1133966-21-8 (E)-methyl 7-oxo-7-(2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)phenylamino)heptanoate 
• 885126-35-2 (E)-N-methyl-2-{[3-(2-(pyridin-2-yl)ethenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl]thio}benzamide 
• 319460-85-0 axitinib 

Relevant articles and documents

2,3-dimethyl-6-urea -2H-indazoles and its preparation method and application

The invention discloses a 2, 3-dimethyl-6-urea-2H-indazole compound shown by the following general formula (I), medicinal salt or a solvent compound thereof, wherein Ar is substituted or unsubstituted phenyl or aromatic matrix. The invention also discloses a preparation method and application of the compound. The compound can regulate signal transduction of tyrosine kinase, inhibit bad cellular proliferation, and particularly has obvious curative effect for tumors.

A process for the preparation of intermediates axi for Nepal the preparation and application of axi for Nepal

The invention relates to a method for preparing an intermediate of axitinib and application of the intermediate in preparation of axitinib. The preparation method for the intermediate of axitinib 3-iodine-6-nitro-1-(teralin-2H-pyran-2-base)-1H-indazole comprises the following steps that 6-nitroindazole and 3,4-dihydro-2H-pyran react under the action of catalyst so as to protect perssad tetralin-2H-pyran-2-base at N-H site, and the key intermediate with high yield is obtained through iodination at site 3. The application of the intermediate in preparation of axitinib is as follows: Heck coupled reaction is carried out on the intermediate and 2-vinyl pyridine, then nitro reduction and diazo-reaction for iodination are sequentially carried out, finally, the axitinib is obtained after docking of 2-sulfydryl-N-methyl benzamide and deprotection. The related main initial raw materials are easy to purchase in markets, and the method has high yield and high molecule economic efficiency, is efficient and environment-friendly, and is suitable for industrial mass production.

VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to VEGFR inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.

METHODS FOR PREPARING INDAZOLE COMPOUNDS

The invention relates to methods for preparing indalzole compounds having formula (I) or pharmaceutically acceptable salts or solvates thereof. Compounds of the formula (I) are useful as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer or other diseases associated with cellular proliferation mediated by protein kinases.

METHODS FOR PREPARING INDAZOLE COMPOUNDS

The invention relates to methods for preparing compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof. Compounds of the formula (I) are useful as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer or other diseases associated with cellular proliferation mediated by protein kinases.